Patent ID: 7211572
Filing Date: 2007-05-01
Classification: A61P,C07D

Abstract:
1. A nitrogen-containing fused ring compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein R (1) a C1–6 alkyl group optionally substituted by 1 to 3 substituent(s) selected from the following group A, (2) a C2–6 alkenyl group optionally substituted by 1 to 3 substituent(s) selected from the following group A or (3) a group represented by the formula wherein Z is  wherein Q is  (1″) —O—,  (2″) —NR  wherein R  (3″) —CO—,  (4″) —SO—, or  (5″) —SO  m is 0 or an integer of 1 to 4,  n is 0 or an integer of 1 to 4 and  * shows the side to be bonded to a nitrogen atom of ring A, and  (1′) a C3–10 carbon ring group optionally substituted by 1 to 3 substituent(s) selected from the following group B or  (2′) a heterocyclic group optionally substituted by 1 to 3 substituent(s) selected from the following group B wherein the heterocyclic group contains at least one hetero atom selected from a nitrogen atom, oxygen atom and sulfur atom; X is (1) —C(R (2) —C(R (3) —C(R (4) —C(R (5) —C(R (6) —C(R wherein # shows the side to be bonded to Y of ring B is (1) C═C(R (2) N—C(R (3) N—C(R (4) C═N—N(R (5) N—N═C(R when is N—C(R y1 )═C(R y2 ), ring B is optionally condensed with a benzene ring to form a fused ring represented by wherein R group A; (1) a halogen atom, (2) a cyano group, (3) —OR (4) —SR (5) —CO (6) —CONR (7) —COR (8) —SO (9) —SO (10) a C6–14 aryloxy group, and (11) a C6–14 aryl C1–6 alkyloxycarbonyl group, wherein R group B: (1) a halogen atom, (2) a cyano group, (3) a C1–6 alkyl group, (4) a halo C1–6 alkyl group, (5) —OR (6) —SR (7) —CO (8) —CONR (9) —COR (10) —SO (11) —SO (12) a C6–14 aryloxy group, and (13) a C6–14 aryl C1–6 alkyloxycarbonyl group, group C: (1) a hydrogen atom, (2) a cyano group, (3) a halogen atom, (4) a methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, tert-pentyl group, or hexyl group, (5) a C2–6 alkenyl group, (6) a C2–6 alkynyl group, (7) a C6–14 aryl group, (8) a group selected from pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, thienyl, furyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, and 1,3,4-thiadiazolyl, (9) a C1–6 alkyloxy group, (10) a C6–14 aryl C1–6 alkyl group, (11) a C6–14 aryl C1–6 alkyloxy group, (12) —CO (13) —CONR (14) —COR (15) —SO (16) a C6–14 arylcarbonyl group, wherein R (1′) a hydrogen atom, or (2′) a methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, tert-pentyl group, or hexyl group, each of which is optionally substituted by 1 to 3 substituent(s) selected from the above-mentioned group A, the methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, tert-pentyl group, hexyl group, C1–6 alkyl moiety, C2–6 alkenyl group and C2–6 alkynyl group of the above-mentioned group C are optionally substituted by 1 to 3 substituent(s) selected from the above-mentioned group A; and the C6–14 aryl group, C6–14 aryl moiety and the pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, pyrrolyl, pyrazolyl, imidazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, thienyl, furyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, and 1,3,4-thiadiazolyl group of the above-mentioned group C are optionally substituted by 1 to 3 substituent(s) selected from the above-mentioned group B.